Clinical Trials Logo

Clinical Trial Summary

The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04997252
Study type Interventional
Source Zhujiang Hospital
Contact Zhang yiming
Phone 020-62782726
Email 59281481@qq.com
Status Recruiting
Phase N/A
Start date February 1, 2021
Completion date December 2024